Preston E Bratcher
Overview
Explore the profile of Preston E Bratcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
713
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nick H, Christeson S, Bratcher P
Int J Mol Sci
. 2025 Jan;
26(2.
PMID: 39859187
The cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel that is dysfunctional in individuals with cystic fibrosis (CF). The permeability of CFTR can be experimentally manipulated though different...
2.
Nick H, Christeson S, Bratcher P
Biomolecules
. 2024 Nov;
14(11).
PMID: 39595555
VX-770 is a small-molecule CFTR potentiator that is highly efficacious in individuals with cystic fibrosis caused by mutations in CFTR that result in a defect in channel gating. While studies...
3.
Nick H, Johnson C, Stewart A, Christeson S, Bloomquist L, Appel A, et al.
J Pharmacol Exp Ther
. 2023 Aug;
388(2):576-585.
PMID: 37541763
Inhalation of high levels of sulfur mustard (SM), a potent vesicating and alkylating agent used in chemical warfare, results in acutely lethal pulmonary damage. Sodium 2-mercaptoethane sulfonate (mesna) is an...
4.
Hinds D, Nick H, Vallin T, Bloomquist L, Christeson S, Bratcher P, et al.
Am J Physiol Lung Cell Mol Physiol
. 2022 Aug;
323(5):L525-L535.
PMID: 36041220
E-cigarette vaping is a major aspect of nicotine consumption, especially for children and young adults. Although it is branded as a safer alternative to cigarette smoking, murine and rat models...
5.
Kotas M, Moore C, Gurrola 2nd J, Pletcher S, Goldberg A, Alvarez R, et al.
JCI Insight
. 2022 May;
7(13).
PMID: 35608904
Chronic type 2 (T2) inflammatory diseases of the respiratory tract are characterized by mucus overproduction and disordered mucociliary function, which are largely attributed to the effects of IL-13 on common...
6.
Shaughnessy C, Zeitlin P, Bratcher P
J Cyst Fibros
. 2022 Mar;
21(4):637-643.
PMID: 35248469
Background: A decrease in the lumacaftor-mediated increase in F508del-CFTR function and expression upon prolonged exposure to ivacaftor (VX-770) has previously been described. However, the efficacy observed with ivacaftor-containing CFTR modulator...
7.
Shaughnessy C, Yadav S, Bratcher P, Zeitlin P
Am J Physiol Lung Cell Mol Physiol
. 2022 Jan;
322(3):L305-L314.
PMID: 35020527
Cystic fibrosis (CF) is a genetic disease caused by mutations of the gene encoding a cAMP-activated Cl channel, the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR modulator therapies consist of...
8.
Nick H, Zeitlin P, Yadav S, Bratcher P
Sci Rep
. 2021 Nov;
11(1):22616.
PMID: 34799640
Quantitation of CFTR function in vitro is commonly performed by acutely stimulating then inhibiting ion transport through CFTR and measuring the resulting changes in transepithelial voltage (V) and current (I)....
9.
Shaughnessy C, Zeitlin P, Bratcher P
Sci Rep
. 2021 Oct;
11(1):21295.
PMID: 34697341
No abstract available.
10.
Shaughnessy C, Zeitlin P, Bratcher P
Sci Rep
. 2021 Oct;
11(1):19810.
PMID: 34615919
Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), which lead to early death due to progressive lung disease. The development of small-molecule modulators...